Sofosbuvir Meets Goals in Hepatitis C Trials
Gilead’s two hepatitis C drug trials meet study goals
(Reuters) – Biotechnology company Gilead Sciences on Monday said two trials of its hepatitis C drug, the centerpiece of its oral hepatitis C treatment program, met their goals in two late-stage studies.
The results are expected to be used to support the company’s regulatory filing seeking approval in the United States. Industry analysts say the market for such drugs could reach $25 billion by 2020.
An estimated 4 million Americans have the virus, with 170 million infected worldwide.
Gilead’s hepatitis C drugs program is considered among the most advanced of many companies racing to bring an interferon-free treatment regimen to market. The newer hepatitis C drugs, while doubling the cure rate of prior treatments, must still be taken with interferon, which causes miserable flu-like symptoms that lead many patients to discontinue or put off treatment.
Continue reading this entire article: